Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbbVie Inc (ABBV) vs Newegg Commerce Inc (NEGG) Price & Performance

AbbVie IncTrade
Newegg Commerce IncTrade

Price performance (Past 24H)

Key statistics

AbbVie Inc vs Newegg Commerce Inc — how do they compare? AbbVie Inc trades at $249.72 (market cap $441.94B), while Newegg Commerce Inc trades at $18.51 (market cap $398.29M). The key difference: AbbVie Inc is far larger — about 1109.6× Newegg Commerce Inc's market cap, and AbbVie Inc pays a 2.77% dividend while Newegg Commerce Inc pays none. Which is the better fit depends on your goals.

ABBVNEGG
Market Cap
$441.94B$398.29M
Sector
HealthConsumer Cyclical
52-Week High
$263.58$128.09
52-Week Low
$197.38$12.87
Enterprise Value
$506.19B$397.09M
Dividend Yield
2.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbbVie Inc

AbbVie (ABBV) trades at $247.91, up 0.76% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 70.73% buy consensus highlight robust fundamentals, driven by Skyrizi and Rinvoq growth offsetting Humira declines. Positive news includes Phase 2 ovarian cancer data and institutional stake increases, reinforcing momentum.

Outlook remains positive with a $278.69 price target, though risks include patent cliffs and debt levels. Revenue growth and dividend stability offer appeal, but investors should monitor competitive pressures and regulatory developments for sustained performance.

Newegg Commerce Inc

Newegg Commerce (NEGG) trades at $18.38, up 8.76% in the last session, with a bullish technical outlook and recent earnings beats. The company reported revenue of $1.44 billion for 2025, with a net loss narrowing to $4.88 million, showing improved profitability trends. Recent news highlights AI shopping features and exclusive product launches, indicating innovation efforts.

The outlook is cautiously optimistic due to earnings improvement and positive analyst sentiment, but risks include volatile cash flows, high P/E ratio, and competitive pressures in e-commerce. Institutional interest remains limited, with one analyst rating the stock a Buy as of 2026-08-12.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbbVie Inc

AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

Read more on ABBV

About Newegg Commerce Inc

Newegg Commerce Inc is an e-commerce company offering direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products and provides certain third-party logistics services globally.

Read more on NEGG